Ohana MedSpas

Ohana MedSpas operates in Honolulu, Hawaii, under the medical direction of Dr. Carolyn Candido, a board-certified Family Medicine physician with additional certification in Aesthetic Medicine. The clinic focuses on medically supervised weight management programs that integrate GLP-1 receptor agonist peptide therapies with comprehensive metabolic assessment and ongoing clinical monitoring. Dr. Candido's dual certification allows the practice to address both the functional medicine aspects of metabolic health and the aesthetic concerns that often accompany significant weight changes, providing patients with coordinated care throughout their treatment journey.

The clinic's weight management protocols center on two FDA-approved peptide therapies: Semaglutide and Tirzepatide. Semaglutide, a GLP-1 receptor agonist, works by mimicking incretin hormones that regulate insulin secretion and appetite signaling, while Tirzepatide functions as a dual GIP/GLP-1 receptor agonist, engaging both glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 pathways. Patients receive individualized dosing protocols based on their metabolic profile, body composition analysis, and response to treatment. The medical team adjusts peptide dosages according to tolerance, efficacy markers, and weight loss progression, with regular follow-up appointments to monitor cardiovascular parameters, glycemic control, and potential side effects. Each program includes baseline laboratory work, body composition measurement, and nutritional counseling to optimize outcomes beyond pharmacological intervention alone.

Dr. Candido's background in Family Medicine provides a foundation for evaluating patients' complete medical histories, including comorbid conditions such as hypertension, dyslipidemia, and insulin resistance that frequently accompany excess adiposity. Her aesthetic medicine training enables the practice to address skin laxity, volume loss, and body contour concerns that may emerge during significant weight reduction. This integrated approach means patients can access complementary treatments within the same clinical setting, rather than coordinating care across multiple providers. The clinic's treatment philosophy emphasizes sustainable metabolic changes rather than rapid weight loss, with protocols designed to preserve lean muscle mass and support long-term weight maintenance after peptide therapy completion.

Patients beginning treatment at Ohana MedSpas in Honolulu undergo an initial consultation that includes medical history review, physical examination, and discussion of realistic weight loss expectations based on clinical data. The clinic provides clear information about the mechanism of action for each peptide option, common side effects such as nausea and gastrointestinal changes, and the typical timeline for therapeutic response. Follow-up visits occur at intervals determined by the specific peptide protocol and individual patient needs, with most patients seen monthly during the titration phase. The practice maintains communication channels for patients to report concerns between scheduled appointments, and adjusts treatment plans based on tolerance and progress. With a Google rating of 4.9 stars across 82 reviews, the clinic has established a track record of patient satisfaction in the Honolulu medical aesthetics and weight management community.

Ohana MedSpas serves patients throughout Honolulu and the broader Oahu area, offering appointment scheduling that accommodates working professionals and families. The clinic's location in Hawaii's capital city provides access to a patient population seeking alternatives to traditional diet-and-exercise-only approaches for weight management. Dr. Candido's certification in both Family Medicine and Aesthetic Medicine distinguishes the practice from weight loss clinics staffed by providers without comprehensive medical training or aesthetic facilities that add peptide therapy without appropriate metabolic medicine expertise. The practice maintains current protocols aligned with emerging clinical data on GLP-1 therapies, adjusting treatment approaches as new research informs best practices for dosing, duration, and patient selection for Semaglutide and Tirzepatide therapy.